Dyslipidémie - Historique des versions

Julien : /* Prévention primaire */

2021-10-14T13:51:21Z

Prévention primaire

2021-10-14T13:50:50Z

Prévention secondaire

2021-10-14T13:50:16Z

Prévention secondaire

2021-10-14T13:49:48Z

Prévention primaire

2021-10-14T13:49:15Z

Prévention primaire

2021-10-14T13:47:23Z

Prévention primaire

2021-10-14T13:46:47Z

Prévention primaire

2021-10-14T13:46:16Z

Prévention primaire

2021-10-14T13:43:44Z

Prévention secondaire

2021-10-14T13:42:53Z

Prévention primaire

@@ Ligne 30 : / Ligne 30 : @@
 :: the U.S. Preventive Services Task Force (USPSTF) recommends statin therapy for the primary prevention of ASCVD.
 * <u>Avec calcul du score de risque au préalable:</u>
-** Patients with a 10-year risk for ASCVD of 20% or higher.
+** Patients with a '''10-year risk for ASCVD of 20% or higher'''.
 === Prévention secondaire ===

@@ Ligne 33 : / Ligne 33 : @@
 === Prévention secondaire ===
-* Chez les patients suivants (= atteints d'ASCVD):
+* <u>Chez les patients suivants (= atteints d'ASCVD):</u>
 ** [[Syndrome coronarien aigu]]
 ** Antécédent d'infarctus du myocarde

@@ Ligne 42 : / Ligne 42 : @@
 ** [[Anévrisme aortique]]
-; → High-intensity statin therapy should be initiated in patients with ASCVD who are aged ≤ 75 years to achieve a reduction in LDL cholesterol of 50% or greater.
+: → High-intensity statin therapy should be initiated in patients with ASCVD who are aged ≤ 75 years to achieve a reduction in LDL cholesterol of 50% or greater.
-; → If high-intensity statin therapy is contraindicated or not tolerated, moderate-intensity statin therapy should be initiated to achieve a reduction in LDL cholesterol of 30% to 49%.
+: → If high-intensity statin therapy is contraindicated or not tolerated, moderate-intensity statin therapy should be initiated to achieve a reduction in LDL cholesterol of 30% to 49%.
 === Laboratoire ===

@@ Ligne 28 : / Ligne 28 : @@
 *** at least one ASCVD risk factor (dyslipidemia, diabetes, hypertension, or smoking) '''<u>and</u>'''
 *** a calculated 10-year ASCVD risk of 10% or greater
-**: the U.S. Preventive Services Task Force (USPSTF) recommends statin therapy for the primary prevention of ASCVD.
+:: the U.S. Preventive Services Task Force (USPSTF) recommends statin therapy for the primary prevention of ASCVD.
 * <u>Avec calcul du score de risque au préalable:</u>
 ** Patients with a 10-year risk for ASCVD of 20% or higher.

@@ Ligne 28 : / Ligne 28 : @@
 *** at least one ASCVD risk factor (dyslipidemia, diabetes, hypertension, or smoking) '''<u>and</u>'''
 *** a calculated 10-year ASCVD risk of 10% or greater
-**; the U.S. Preventive Services Task Force (USPSTF) recommends statin therapy for the primary prevention of ASCVD.
+**: the U.S. Preventive Services Task Force (USPSTF) recommends statin therapy for the primary prevention of ASCVD.
 * <u>Avec calcul du score de risque au préalable:</u>
 ** Patients with a 10-year risk for ASCVD of 20% or higher.

@@ Ligne 25 : / Ligne 25 : @@
 ** Adults of '''any age''' with an LDL cholesterol level of 4.92 mmol/L or higher should be started on high-intensity statin therapy<ref>American Heart Association/American College of Cardiology cholesterol treatment guideline</ref>
 ** Adults '''aged 40 to 75 years''' with diabetes should be started on moderate-intensity statin therapy.
-** In adults aged '''40 to 75 years''' who have at least one ASCVD risk factor (dyslipidemia, diabetes, hypertension, or smoking) and a calculated 10-year ASCVD risk of 10% or greater, the U.S. Preventive Services Task Force (USPSTF) recommends statin therapy for the primary prevention of ASCVD.
+** In adults aged '''40 to 75 years''' who have:
 * <u>Avec calcul du score de risque au préalable:</u>
 ** Patients with a 10-year risk for ASCVD of 20% or higher.